New CHMP Chair Sought As Salmonson’s Tenure At Key EMA Panel Ends
Executive Summary
Tomas Salmonson, the longstanding chair of the European Medicines Agency's key scientific committee, the CHMP, is being replaced. The Swedish regulator has held the post for six years, the maximum time allowed.
You may also be interested in...
CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due
The European Medicines Agency’s key scientific committee, the CHMP, is deciding whether a raft of new products, including Eli Lilly’s galcanezumab, should be approved for sale across the EU. Sarepta’s appeal of the CHMP’s earlier rejection of its marketing application for Exondys is also slated for a decision.
CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due
The European Medicines Agency’s key scientific committee, the CHMP, is deciding whether a raft of new products, including Eli Lilly’s galcanezumab, should be approved for sale across the EU. Sarepta’s appeal of the CHMP’s earlier rejection of its marketing application for Exondys is also slated for a decision.
Sabine Straus To Lead EMA's Pharmacovigilance Committee
Dutch regulator Sabine Straus will take over as chair of the European Medicines Agency's Pharmacovigilance Risk Assessment Committee when the UK’s June Raine leaves the post this year.